Can a cancer drug tame tangled blood vessels?
NCT ID NCT07037238
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests the oral drug everolimus in 10 adults with vascular malformations—abnormal clusters of blood vessels. The goal is to see if the drug can shrink these lesions and reduce complications like bleeding. Participants take everolimus daily for up to a year, with MRI scans tracking changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus (an oral drug that blocks a protein called mTOR)
What this could lead to
If it works, this could point toward a non-surgical treatment option for vascular malformations, potentially reducing lesion size and bleeding risk.
What could go wrong
This is a very small, early-phase trial with only 10 participants and no comparison group. The drug may not shrink lesions or could cause side effects like mouth sores, infections, or metabolic changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••